Regeneron

News

GSK says Nucala hits the target in new COPD trial

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial.<

News

Regeneron joins Koneksa Parkinson's digital biomarker study

Regeneron is the second pharma group to sign up for access to data from a remote study run by health technology firm Koneksa that is exploring the use of digital biomarkers to track patient

News

After FDA no, Regeneron gets yes from EU on odronextamab

Regeneron's CD20xCD3 bispecific antibody for non-Hodgin lymphoma (NHL) has been approved in Europe, five months after it was turned down by the FDA in the US.

News

Galderma's chief executive Flemming Ørnskov

Galderma gets FDA nod for prurigo nodularis therapy

Dermatology specialist Galderma has FDA approval for prurigo nodularis treatment Nemluvio, one of two new drugs that it thinks will deliver blockbuster sales.

News

Close-up image of a melanoma on the skin

BioNTech cancer vaccine hits the spot in melanoma

mRNA specialist BioNTech has chalked up an important win in its cancer pipeline, showing efficacy with its BNT111 vaccine candidate in a phase 2 trial in advanced melanoma.

News

EU first to approve Dupixent for COPD

Chronic obstructive pulmonary disease (COPD) has seen no new therapies brought to market for around 10 years – and now there have been two in the space of a couple of weeks.

GSK says Nucala hits the target in new COPD trial

Regeneron joins Koneksa Parkinson's digital biomarker study

After FDA no, Regeneron gets yes from EU on odronextamab

Galderma gets FDA nod for prurigo nodularis therapy

BioNTech cancer vaccine hits the spot in melanoma

EU first to approve Dupixent for COPD

FDA launches pilot programme to boost US manufacturing

How to meet your physicians where they are online

Regeneron

Editor's Picks